TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2850326
Drug: Alfa LMW1
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfa LMW1 (8,000 I.U. AXa daily for 6 months)
Study: 23764248
Drug: Same amount
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same amount of intravenous contrast in both CCTA examinations
Study: 23764248
Drug: 0.7 mL/mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mL/mg body weight of contrast medium (350 mgI/mL) for baseline and follow-up CCTAs
Study: 21992655
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (ICBT) for 10 weeks, guided by an online therapist, focusing on acceptance of symptoms through exposure and mindfulness training.
Study: 17176013
Drug: Nonoperative therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative therapies
Study: 11084187
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (15 mg for 8 weeks, then 10 mg for 3 weeks)
Study: 1281015
Drug: FUT (nafamostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT (nafamostat mesilate) 2 mg/kg/hr during CPB and 0.2 mg/kg/hr before and after CPB
Study: 6146752
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg daily for 14 days)
Study: 27098971
Drug: Integrated, multifaceted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated, multifaceted package of interventions including delayed prescribing, patient decision aids, communication training, commitment to a practice prescribing policy for antibiotics, patient information leaflet, and near patient testing with C-reactive protein.
Study: 20466698
Drug: Antibiotic impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic impregnated catheters (Bactiseal)
Study: 20466698
Drug: Conventional catheters
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheters with systemic antibiotics
Study: 18361280
Drug: Individual therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapies
Study: 18361280
Drug: Vitamin and
Normalized name: Vitamin and Mineral Supplement
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin and calcium supplements
Study: 7750585
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide acetate (3.75 mg JM depot LA given every month and daily placebo tablets)
Study: 7750585
Drug: Danazol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (800 mg oral danazol daily with a monthly placebo injection)
Study: 25809579
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment for 1 year
Study: 25809579
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (meta-analysis of eight trials)
Study: 23650431
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nebulized furosemide
Study: 11558026
Drug: Vasoconstrictive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstrictive treatment (vasopressin/terlipressin)
Study: 11558026
Drug: Vasoactive treatment
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive treatment (somatostatin/octreotide)
Study: 9761517
Drug: Felodipine (ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (ER tablets, 10 mg)
Study: 3341541
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of sodium hydroxide
Study: 3341541
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of saline solution or hydrochloric acid
Study: 17520505
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (AChE-I) including donepezil, galantamine, and rivastigmine
Study: 17520505
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (AChE-I)
Study: 14560174
Drug: QD (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD (10 mg of Adderall at 7:30 a.m. and placebo at noon)
Study: 14560174
Drug: BID (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (10 mg of Adderall at 7:30 a.m. and at noon)
Study: 8226444
Drug: Ambient [Hb]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient [Hb] of 15.9 ± 0.7 g/100 ml breathing 21 or 12% O2
Study: 8226444
Drug: Decreased [Hb]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased [Hb] to 13.8 ± 0.6 g/100 ml by venesection and isovolemic replacement with 5% albumin in 0.9% saline
Study: 8226444
Drug: Decreased [Hb]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased [Hb] to 13.8 ± 0.6 g/100 ml
Study: 26694209
Drug: Tranexemic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexemic acid (1 g) administered after induction
Study: 24036634
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) for 12 weeks with peg-interferon/ribavirin (peg-IFN/RBV) for 48 weeks
Study: 22746973
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL) plus the LTRA pranlukast (PRL) for 2 weeks
Study: 22746973
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL) alone
Study: 20144246
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum MF1298 (10^10 CFU)
Study: 15889583
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group treatment (CBGT) administered over 8, 90 min weekly sessions
Study: 15889583
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (wait list)
Study: 15552855
Drug: Daily toothbrushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily toothbrushing under supervision of trained teacher
Study: 15552855
Drug: Daily toothbrushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily toothbrushing under supervision of parents
Study: 10544378
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at an initial dose of 0.125 U/kg/week for the first month, then 0.25 U/kg/week
Study: 8688278
Drug: Crystalloid-hydroxyethylstarch combination
Normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid-hydroxyethylstarch combination (lactated Ringer's solution 1000 ml with up to 1000 ml of 6% hydroxyethylstarch)
Study: 8688278
Drug: Colloid without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid without crystalloid (up to 1000 ml of 6% hydroxyethylstarch)
Study: 8688278
Drug: Crystalloid-gelatin combination
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid-gelatin combination (lactated Ringer's solution 1000 ml with up to 1000 ml of modified gelatin)
Study: 6664154
Drug: Naloxone (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (32 mg)
Study: 6664154
Drug: Tilidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (100 mg) + Naloxone (8 mg)
Study: 6664154
Drug: Tilidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilidine (100 mg) + Naloxone (32 mg)
Study: 27243803
Drug: Nivolumab 0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 0.3, 2, or 10 mg/kg intravenously every 3 weeks
Study: 23034262
Drug: Alprostadil (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (prostaglandin E) administration during surgery
Study: 15111966
Drug: Rectal resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal resection with lowest percent of purulent complications
Study: 12460130
Drug: MET/CBT5 (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET/CBT5 (6-week intervention with 2 sessions of individual motivational enhancement therapy plus 3 sessions of group cognitive behavioral therapy)
Study: 12460130
Drug: MET/CBT12 (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET/CBT12 (12-week intervention with 2 sessions of motivational enhancement therapy plus 10 sessions of group cognitive behavioral therapy)
Study: 12460130
Drug: MDFT (multi-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDFT (multi-dimensional family therapy)
Study: 8542099
Drug: Chronic intermittent
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic intermittent intravenous insulin therapy (CIIIT)
Study: 2682969
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid combination (group A)
Study: 2682969
Drug: Penicillin, aminoside,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin, aminoside, and metronidazole combination (group B)
Study: 4830231
Drug: Active ileal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ileal absorption of chenodeoxycholic acid
Study: 4830231
Drug: Active ileal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ileal absorption of glycochenodeoxycholic acid
Study: 4830231
Drug: Active ileal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ileal absorption of taurocholic acid
Study: 4830231
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of absorption rates
Study: 22696911
Drug: Both beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta blockers (Carvedilol and Propranolol)
Study: 19046483
Drug: ADHD subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD subjects off medication for 24 hours
Study: 19046483
Drug: ADHD subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD subjects on medication
Study: 17218764
Drug: ASA‐VitC (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA‐VitC (1.6 g ASA + 0.96 g Vit C/day)
Study: 17218764
Drug: ASA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (1.6 g ASA/day)
Study: 8720309
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of commercial enteric coated tablet
Study: 2010637
Drug: 566C80 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 566C80 3000 mg once daily for 12 days
Study: 2010637
Drug: 566C80 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 566C80 750 mg three times daily for 5 days, then twice daily for 16 days
Study: 2010637
Drug: 566C80 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: 566C80 (various dosages: 100, 250, 750, 1500 mg)
Study: 7035299
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g daily for three days)
Study: 7035299
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of encephalopathy, serum bilirubin > 340 micromol/l, serum creatinine > 250 micromol/l, histological evidence of cirrhosis
Study: 24742364
Drug: Oral iodinated
Normalized name: iodine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iodinated activated charcoal (IAC)
Study: 22728413
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (CAF‐‐5 mg · kg(‐1))
Study: 16238677
Drug: Dalteparin 120
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 120 IU kg(‐1) s.c. twice daily for 5‐7 days followed by 5,000 or 7,500 IU twice daily for 3 months
Study: 9440409
Drug: 2-week clerkship
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week clerkship in physical medicine and rehabilitation
Study: 7879323
Drug: High energetic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energetic shock wave treatment (Lithotripter MFL 5000, 2000 impulses per session, 2 sessions, energy 18 kV‐22 kV)
Study: 7879323
Drug: High energetic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energetic shock wave treatment
Study: 2295223
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan (0.25 mg/kg) alone
Study: 2295223
Drug: Oral melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral melphalan (0.25 mg/kg) after interferon (7 x 10(6) IU/m2)
Study: 6154110
Drug: Interferon administration
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon administration
Study: 20405054
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/day)
Study: 28406394
Drug: Prednisolone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.5 mg/kg/day)
Study: 25331030
Drug: Ipamorelin 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipamorelin 0.03 mg/kg intravenous infusion twice daily
Study: 19887796
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin (4 mg loading dose followed by 2 mg daily for 30 days)
Study: 19887796
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin
Study: 10440971
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) for 1 hour per day for 4 weeks
Study: 7752281
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg or 40 mg of lovastatin
Study: 1982614
Drug: Azatadine 1
Normalized name: azatadine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azatadine 1 mg twice daily
Study: 28685973
Drug: Exenatide QWS-AI
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QWS-AI (2 mg)
Study: 27815351
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week from Week 4 to Week 52
Study: 19338141
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of lamivudine 40 mg and stavudine 10 mg tablet for oral suspension
Study: 19338141
Drug: Individual liquid
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual liquid formulations of lamivudine and stavudine
Study: 12184348
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for depression (8 weeks duration)
Study: 12184348
Drug: Established treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established treatments for Major Depression
Study: 7862838
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triazolam
Study: 29789410
Drug: Subcutaneous ATL1103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ATL1103 200 mg twice weekly for 13 weeks
Study: 29789410
Drug: Subcutaneous ATL1103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ATL1103 200 mg once weekly for 13 weeks
Study: 15319242
Drug: docetaxel 40
Normalized name: docetaxel 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 40 mg/m2 weekly for 6 consecutive weeks followed by 2 weeks without treatment (n = 41)
Study: 15319242
Drug: docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 100 mg/m2 on day 1 every 3 weeks (n = 42)
Study: 8218959
Drug: Disopyramide formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide formulation 1 (100 mg)
Study: 8218959
Drug: Disopyramide formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide formulation 2 (100 mg)
Study: 25012121
Drug: Acupuncture therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy, treatment three times a week for 5 weeks.
Study: 25012121
Drug: Cupping therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy, treatment three times a week for 5 weeks.
Study: 15868003
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of SG to PG after topical vasodilator application
Study: 2509916
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of recombinant interferon alfa three times weekly for 24 weeks
Study: 2509916
Drug: 1 million
Normalized name: Nystatin 1 MILLION U Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 million units of recombinant interferon alfa three times weekly for 24 weeks
Study: 31567876
Drug: HALC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HALC with MIAT level <10.9 in CC tissue or <8.7 in serum
Study: 23524149
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion at a rate of 0.4 μg kg(‐1) h(‐1)
Study: 26329913
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at a rate of 0.05 μg kg(‐1) min(‐1)
Study: 19464166
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and vinorelbine combination therapy
Study: 19464166
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine added to capecitabine
Study: 19464166
Drug: Capecitabine-vinorelbine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine-vinorelbine combination
Study: 3528055
Drug: Simultaneous methotrexate-5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous methotrexate-5-fluorouracil chemotherapy
Study: 3528055
Drug: 1-hour sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour sequential methotrexate-5-fluorouracil chemotherapy
Study: 3528055
Drug: Radical radiation
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiation therapy after chemotherapy
Study: 3528055
Drug: Chemotherapy responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy responders treated with radiation
Study: 3528055
Drug: Chemotherapy nonresponders
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy nonresponders treated with radiation
Study: 28432210
Drug: Complex intervention
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex intervention combining personalised feedback on home air quality, behavioural support and nicotine replacement therapy for temporary abstinence
Study: 25519680
Drug: PXT3003 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXT3003 high dose (HD)
Study: 22471133
Drug: Acupuncture-moxibustion-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion-medication group (25 cases)
Study: 22471133
Drug: Acupuncture-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-medication group (25 cases)
Study: 22471133
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (30 cases)
Study: 20441458
Drug: Written emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written emotional expression treatment
Study: 9313058
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered orally (25 to 50 mg/kg divided into 2 portions) for 14‐42 days
Study: 9313058
Drug: Ciprofloxacin administered
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin administered intravenously (10 to 23 mg/kg injected twice a day) for 14‐18 days
Study: 8311697
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (30 sessions)
Study: 8311697
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (20 sessions)
Study: 8311697
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (15 sessions)
Study: 8311697
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (10 sessions)
Study: 30732648
Drug: Var-HSA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Var-HSA group (vaccine without human serum albumin)
Study: 30732648
Drug: Var +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Var + HSA group (vaccine with human serum albumin)
Study: 25618802
Drug: Early weightbearing
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early weightbearing from day 1 of treatment
Study: 19708911
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (2 microg x kg(‐1)) with hyperbaric bupivacaine
Study: 17101710
Drug: 1.2-1.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2-1.8 mg/kg per day (continued same dose)
Study: 17101710
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg per day (low dose)